Monitor for future prospectus supplements that will detail specific offerings, including pricing, size, and use of proceeds. The announcement of an actual offering could lead to share price volatility and dilution.
Price Chart
Executive Summary
Tenax Therapeutics has filed a shelf registration (S-3) to raise up to $300 million through future offerings of common stock, preferred stock, debt securities, warrants, rights, or units. This is a routine capital-raising mechanism allowing the company to issue securities opportunistically over time. The filing itself does not raise capital but signals potential future dilution.
Key Financial Metrics
Key Facts
- Company filed an S-3 shelf registration to offer up to $300 million in securities.
- Securities may include common stock, preferred stock, debt, warrants, rights, or units.
- Offerings will be conducted from time to time at prices and terms determined at the time of sale.
- Proceeds will be used for general corporate purposes, including R&D for levosimendan and imatinib programs.
- The filing is a procedural step and does not immediately raise capital or change the company's financial position.
Financial Impact
Potential future dilution of up to $300 million in equity or debt issuance.
Risk Factors
- Future equity offerings will dilute existing shareholders.
- Offerings may occur at inopportune times or unfavorable prices.
- Proceeds may not be used as efficiently as anticipated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001654954-26-002661 |
| Document: tennx_ex418.htm | 0001654954-26-002661 |
| Document: tennx_ex107.htm | 0001654954-26-002661 |
| Document: tennx_ex51.htm | 0001654954-26-002661 |
| Document: tennx_ex231.htm | 0001654954-26-002661 |
| Document: 0001654954-26-002661-index-headers.html | 0001654954-26-002661 |
| CONTEXT: 10-Q (2025-11-12) | 0001193125-25-277793 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.64 (+20.59%) |
Oct 13, 2026 13d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.64 (+2.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.64 (−10.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.64 (−12.30%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.64 (−13.68%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.64 (−23.00%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.64 (−10.87%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.64 (−88.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers